Author name: Claritas Rx

Commercializing a therapy for rare diseases is a challenging endeavor. With the complexities of patient access, regulatory hurdles, and stakeholder engagement, manufacturers must adopt a carefully crafted strategic framework. In a recent Access USA panel discussion, industry experts shared their valuable perspectives on this topic. The panel featured Justin Bush from Pharavis, Richard Wilson from

Specialty pharmacies (SPs) play a crucial role in delivering complex medications to patients who require ongoing support throughout their treatment journeys. However, the effectiveness of SPs often hinges on timely intervention, efficiency, and seamless collaboration among stakeholders. These challenges are further amplified by time-consuming manual processes, delayed responses, and lack of real-time visibility into patient

Guiding patients through their treatment journey is a critical yet intricate task for patient services teams. One of the biggest obstacles they face is “patient drop-off,” the moments when individuals disengage or discontinue treatment. These drop-offs can significantly impact healthcare outcomes, operational efficiency, and access to care. This blog explores the key stages in the

Macular telangiectasia (MacTel) type 2, a rare neurodegenerative eye condition, has long left many without access to effective treatment. This disease silently affects central vision, making everyday tasks like reading and recognizing faces increasingly challenging for those impacted. However, patients and biopharma professionals alike have reason to look ahead with renewed optimism. On March 6,

Every year, millions of people around the world come together to show support and amplify the voices of those living with rare diseases. Rare Disease Day, observed on February 28 (or 29th on leap years), is a vital opportunity to increase public awareness and understanding of rare diseases, their impact, and the need for more

The treatment landscape for rare diseases is rapidly evolving, offering both opportunities and challenges for biopharma professionals and patient service teams. With over 7,000 known rare diseases affecting an estimated 300 million people globally, the need for innovation and collaboration has never been greater. Yet, rare diseases are often underfunded, understudied, and misunderstood, leaving many

Rare diseases affect approximately 30 million people in the United States, yet the path to diagnosing and treating these conditions remains notoriously complex. With small patient populations, high treatment costs, and the necessity for robust engagement strategies, the rare disease sector is filled with challenges. For biopharma professionals, the focus remains on finding innovative ways

The landscape of rare diseases is evolving rapidly, with groundbreaking cell and gene therapies leading the way. These innovative treatments offer hope to patients with diseases previously considered untreatable. However, with innovation comes complexity—bringing these therapies to market isn’t just about scientific breakthroughs but also navigating unique market access challenges. This blog dives into the